TABLE 3.

Regional deposition predictions for administration of three lots of a potential generic version of tiotropium bromide inhalation powder with a strength of Eq 0.018 mg Base/inh, where Lots A, B, and C have measured fine‐particle doses of 3.39 μg, 3.37 μg, and 4.45 μg, respectively.

	Extrathoracic	Tracheobronchial	Bronchiolar	Alveolar–Interstitial
Lot A	53.54	10.33	5.47	30.58
Lot B	56.86	12.00	5.75	25.29
Lot C	41.32	10.54	6.25	41.40